An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Xylo Technologies, formerly known as Medigus , has filed its 2023 Annual Report on Form 20-F, including audited financial statements for the year ended December 31, 2023. The report is available on the company's investor relations website and the SEC's website.
Xylo Technologies, precedentemente conosciuta come Medigus, ha presentato il suo Rapporto Annuale 2023 sul Modulo 20-F, includendo i bilanci controllati per l'anno conclusosi il 31 dicembre 2023. Il rapporto è disponibile sul sito web delle relazioni con gli investitori della società e sul sito web della SEC.
Xylo Technologies, anteriormente conocida como Medigus, ha presentado su Informe Anual 2023 en el Formulario 20-F, incluyendo los estados financieros auditados para el año que terminó el 31 de diciembre de 2023. El informe está disponible en el sitio web de relaciones con inversores de la empresa y en el sitio web de la SEC.
Xylo Technologies는 이전에 Medigus로 알려진 기업으로, 2023년 12월 31일로 종료된 회계 연도에 대한 감사된 재무제표를 포함하여 2023년도 연차보고서를 Form 20-F에 제출했습니다. 이 보고서는 회사의 투자자 관계 웹사이트 및 SEC의 웹사이트에서 확인할 수 있습니다.
Xylo Technologies, anciennement connue sous le nom de Medigus, a déposé son rapport annuel 2023 sur le formulaire 20-F, incluant les états financiers audités pour l'année se terminant le 31 décembre 2023. Le rapport est disponible sur le site web des relations investisseurs de l'entreprise et sur le site web de la SEC.
Xylo Technologies, früher bekannt als Medigus, hat seinen Jahresbericht 2023 auf Formular 20-F eingereicht, einschließlich der geprüften Finanzberichte für das am 31. Dezember 2023 geendete Geschäftsjahr. Der Bericht ist auf der Website für Investorenbeziehungen des Unternehmens und auf der Website der SEC verfügbar.
Positive
None.
Negative
None.
Xylo Technologies' recent filing of its 2023 Annual Report on Form 20-F is a significant disclosure that offers a comprehensive look at the company's financial health over the past year. Analyzing the audited financial statements, investors should examine key metrics such as revenue growth, profit margins and cash flow. These indicators will help in understanding Xylo's operational efficiency and market position. Additionally, comparing year-over-year performance and assessing the management's discussion and analysis (MD&A) section can provide insights into strategic initiatives and risk factors that could influence future performance. Investors should also scrutinize any adjustments or restatements from previous financial reports to ensure a clear understanding of the company's financial trajectory.
In light of Xylo Technologies' annual report, it's essential to contextualize their financial results within the broader industry landscape. By benchmarking Xylo against its peers, one can gauge the company's competitive edge. Market trends, emerging technologies and sector-specific challenges all play a role in shaping Xylo's potential market share and growth opportunities. Understanding how the company is positioned in terms of innovation and adapting to industry shifts can provide indicators of long-term sustainability and potential for return on investment. Consumer demand, regulatory changes and supply chain dynamics are additional factors that must be analyzed to get a well-rounded view of Xylo's prospects.
The filing of the Annual Report on Form 20-F also reflects on Xylo Technologies' commitment to transparency and corporate governance standards. Stakeholders should evaluate the efficacy of internal controls, the clarity of corporate governance policies and the strength of the oversight mechanisms in place. The disclosure of any material weaknesses or legal proceedings in the report is critical information that may impact an investor's confidence in the management team. Furthermore, investor relations practices, such as accessibility and responsiveness to shareholder inquiries, are indicative of a company's regard for shareholder interests.
TEL AVIV, Israel, April 22, 2024 (GLOBE NEWSWIRE) -- Xylo Technologies Ltd. (Nasdaq: XYLO) (“Xylo”, or the “Company”), formerly known as Medigus Ltd., a technology-based company engaged in advanced innovative technologies, announced the filing of its 2023 Annual Report on Form 20-F with the Securities and Exchange Commission.
Xylo’s 2023 Annual Report on Form 20-F includes audited financial statements for the year ended December 31, 2023. The report can be accessed on the company’s investor relations website and on the SEC’s website at www.sec.gov.
About Xylo
Based in Israel, Xylo Technologies Ltd. (Nasdaq: XYLO) is a technologies company that focuses on innovative growth partnerships, mainly in advanced medical solutions, digital commerce, and electric vehicle markets. Xylo’s affiliations in the medical solutions arena include the ownership in Polyrizon Ltd. Xylo’s affiliates in digital commerce include Gix Internet Ltd., Jeffs’ Brands and Eventer Technologies Ltd. In the electric vehicle market, Fuel Doctor, Inc., Charging Robotics, Ltd. and Revoltz Ltd. are also part of Xylo’s portfolio of technology solution providers. Other affiliations of Xylo include Parazero Technologies Ltd. and Zig Miami 54 LLC.
medical device company focused on innovative endoscopic procedures and devices. medigus developed an entire endoscopic system for intraluminal treatment of gerd (gastroesophageal reflux disease), one of the most common chronic diseases in the western world. the endoscopic system for the treatment of gerd - the srs - combines a miniaturized video camera, a surgical stapler and ultrasonic sights for alignment in a single instrument. the srs system and its unique flexible endoscope allows gastroenterologists and surgeons to perform endoluminally a true partial anterior fundoplication, thereby revolutionizing the treatment of gerd by eliminating the need for open or laparoscopic surgery - the current standard practice for treating severe gerd. shifting the gerd treatment from surgery to an endoluminal procedure, without opening the abdominal cavity, is a revolution. in addition, medigus designs and manufactures endoscopy systems for partner companies based on its proprietary technologies,
